A clinical trial to study the effect of Hair4U 10% containing (minoxidil 10% plus Aminexil 1.5%)in treatment of male pattern of baldness

Assessment of Efficacy, Safety and Tolerability of Hair4U 10% (minoxidil 10% plus Aminexil 1.5%) in the treatment of Androgenetic Alopecia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2011/06/001813

Enrollment

Registered

2011-06-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Androgenetic Alopecia

Interventions

Intervention1: Hair4U 10% (minoxidil 10% plus Aminexil 1.5%): 1 ml of study drug aplpied directly on affected area twice a day at interval of 12 hours for 12 weeks. Control Intervention1: NIL: Contro

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with androgenetic alopecia grade from II to IV. Male subjects must be between 18-50years of age. Subject must provide informed consent and comply with protocol.

Exclusion criteria

Exclusion criteria: Subjects not willing to discontinue all the treatments of androgenetic alopecia 2 weeks prior to enrollement in the study. hypersensitivity o any of the ingredients. subjects taking concomitant therapy that might interfere with the study results in investigators opinion. subjects with dermatological disorder of scalp that miht interfere with study evaluation.

Design outcomes

Primary

Measure	Time frame
Reduction in bald areaTimepoint: Reduction in bald area	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Rajesh Lalchandani

rajeshl@glenmarkpharma.com40889082

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026